Ground News

EMSP | European Multiple Sclerosis Platform image

News from EMSP | European Multiple Sclerosis Platform

All of today’s top news stories from EMSP | European Multiple Sclerosis Platform. Get the full analysis behind how media bias impacts breaking news.

Ground News has come across 2 headlines reported on by EMSP | European Multiple Sclerosis Platform during the past 3 months.

We’ve assigned a media bias rating of to EMSP | European Multiple Sclerosis Platform. You can read more about our methodology here.

If you want to know if EMSP | European Multiple Sclerosis Platform is credible or reliable, look no further. We rank EMSP | European Multiple Sclerosis Platform as Unknown factuality. Find out more about our methodology here.

Information about EMSP | European Multiple Sclerosis Platform

Where is EMSP | European Multiple Sclerosis Platform located?EMSP | European Multiple Sclerosis Platform's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top EMSP | European Multiple Sclerosis Platform News

Animals

Vitamin D supplements could reduce multiple sclerosis symptoms, study suggests

100% Right coverage: 1 sources

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis — and a new study suggests that supplementing it in high doses could help reduce symptoms.See the Story

Multiple Sclerosis

Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

Progressive multiple sclerosis (MS) is a severely disabling neurological condition, and an effective treatment is urgently needed. Recently, high-dose…See the Story

You've scrolled to the bottom of the feed, there are no more stories.